The U.S. will likely emerge the winner in a "cold currency war" that is heating up, an expert said.Currenciesread more
These box office numbers do not include the cost of production or marketing costs. They also don't count the billions in merchandising that Disney has made over the last...Entertainmentread more
Tariffs are the only instrument left for addressing China's systematic and excessive surpluses on its U.S. trades, writes Michael Ivanovitch.US Economyread more
In its latest attempt to build market credibility, China on Monday launched the Science and Technology Innovation Board, or "STAR Market," on which 25 companies were listed.China Economyread more
When Cathy Hsu and Tony Hsieh wanted to build an English language app for Chinese children, they decided to follow Facebook and Google's lead.Start-upsread more
Stocks in Asia traded lower on Monday afternoon, as a Nasdaq-style technology board on the Shanghai Stock Exchange marked its debut.Asia Marketsread more
Instagram began tests that hide "like" counts on posts. That means influencers who market products on Instagram will have to rely on different metrics to show success.Technologyread more
Peter Neupert worked for Microsoft and Amazon-backed Drugstore.com, where he got to know Jeff Bezos. He now advises start-ups.Technologyread more
The firing of the tear gas was the latest confrontation between police and protesters who have taken to the streets for over a month to fight a proposed extradition bill and...China Politicsread more
Last week shows that oil prices are not the indicator for Middle East tensions they once were, and worries about global demand and growing U.S. production has changed that...Market Insiderread more
Facebook Vice President David Marcus is the face of the company's Libra digital currency, but the original driving force was a 26-year-old female corporate-development...Technologyread more
Former Valeant CEO J. Michael Pearson unloaded more of his personal holdings than was originally thought, CNBC has learned.
According to documents not made public yet but obtained by CNBC, Pearson sold nearly 5 million shares and options for a total of $96.8 million. The news comes the same day that the Sequoia Fund revealed it is completely out of the stock. Sequoia was at one time the largest Valeant shareholder.
Wednesday also saw short seller Andrew Left say the company's stock could be headed to zero. That news took more than 7 percent out of its shares.
"I think it's obvious it's a zero now," Left told The Street. Left's firm, Citron Research, did not immediately respond to CNBC's request for comment.
Pearson sold about 288,000 shares on June 30 for proceeds of $5.7 million, according to the documents. A day later, he sold more than 4 million shares with proceeds of nearly $83 million, and then on July 5, he sold some 411,000 shares, according to the documents. Total proceeds: $96.8 million.
Valeant told CNBC it was not responsible for filing stock transactions on Pearson's behalf since his employment was terminated in May. Still, a spokesperson for the company said the former CEO "continues to retain a significant ownership position in Valeant."
Shares in the drugmaker were up 2 percent around noon on Wednesday, but then fell to a more than 5 percent decline after news that Left had made a bet against the company.
Valeant, which has been embattled amid U.S. investigations of its business and accounting practices, announced in March that Pearson would leave the company. The company's shares are trading about 90 percent lower than the same time last year, and the price has moved little over the last month.
Also in March, the company slashed its 2016 revenue forecast and said that a delay in filing its annual report could pose a debt default risk. When it finally issued its delayed report, the Canadian drugmaker identified misstatements that would reduce some of its previously reported revenue.
The company came under fire when The New York Times reported that Valeant and other pharmaceutical companies were using a network of specialty pharmacies to sustain sales of their high-priced drugs and prevent patients and insurers from switching to cheaper generic drugs. Citron Research subsequently published a note calling Valeant the "pharmaceutical Enron."
In response, Valeant formed an ad hoc committee to review the allegations regarding specialty pharmacy Philidor RX Services. The U.S. Securities and Exchange Commission is investigating the relationship between the two companies.
"It's been a privilege to lead Valeant for the past eight years. While I regret the controversies that have adversely impacted our business over the past several months, I know that Valeant is a strong and resilient company, and I am committed to doing everything I can to ensure a smooth transition to new leadership," Pearson said in a March statement.
—Reuters and CNBC's Christine Wang and Fred Imbert contributed to this report.